FORM 8-K

-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, N+1I2J2nbvzwU0XvevquP840yNpVlUMHiLVpN4qFeqVfwhT5nk44US4XxIS0vKRk 4cqk/1/9U3eII3nkIDoqcw== 0000950123-06-008002.txt : 20060622 0000950123-06-008002.hdr.sgml : 20060622 20060622171837 ACCESSION NUMBER: 0000950123-06-008002 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 5 CONFORMED PERIOD OF REPORT: 20060613 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20060622 DATE AS OF CHANGE: 20060622 FILER: COMPANY DATA: COMPANY CONFORMED NAME: OSI PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000729922 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 133159796 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-15190 FILM NUMBER: 06920417 BUSINESS ADDRESS: STREET 1: 41 PINELAWN ROAD CITY: MELVILLE STATE: NY ZIP: 11747 BUSINESS PHONE: 631-962-2000 MAIL ADDRESS: STREET 1: 41 PINELAWN ROAD CITY: MELVILLE STATE: NY ZIP: 11747 FORMER COMPANY: FORMER CONFORMED NAME: ONCOGENE SCIENCE INC DATE OF NAME CHANGE: 19920703 8-K 1 y22540e8vk.htm FORM 8-K FORM 8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

Current Report Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934

June 13, 2006

Date of Report (Date of earliest event reported)

OSI PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)


Delaware	0-15190	13-3159796

(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

41 Pinelawn Road
Melville, NY 11747

(Address of principal executive offices)

(631) 962-2000

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

TABLE OF CONTENTS


	ITEM 1.01. Entry Into a Material Definitive Agreement.
	ITEM 9.01. Financial Statements and Exhibits.
SIGNATURE
EXHIBIT INDEX
EX-10.1: FORM OF NON-QUALIFIED OPTION AGREEMENT
EX-10.2: FORM OF NON-QUALIFIED OPTION AGREEMENT
EX-10.3: FORM OF NON-QUALIFIED OPTION AGREEMENT
EX-10.4: EMPLOYMENT AGREEMENT

ITEM 1.01. Entry Into a Material Definitive Agreement.

On June 13, 2006, the Compensation Committee (the “Committee”) of the Board of Directors of OSI Pharmaceuticals, Inc. (“OSI”) approved the grant of non-qualified stock options (“Options”) to each of the executive officers of OSI Pharmaceuticals, Inc., excluding Paul Chaney, who previously received an annual grant of Options in December 2005. Attached hereto as Exhibit 10.1 is the form of non-qualified stock option agreement for OSI’s U.S.-based executive officers and attached hereto as Exhibit 10.2 is the form of non-qualified stock option agreement for OSI’s U.K.-based employees.

On June 14, 2006, each non-management member of the Board of Directors of OSI received an automatic annual grant of stock options upon such member’s election or re-election to the Board. Attached hereto as Exhibit 10.3 is the form of non-qualified stock option agreement for these grants.

On June 21, 2006, OSI and Colin Goddard, Ph.D, the Chief Executive Officer of OSI, executed a technical amendment to Dr. Goddard’s Employment Agreement dated June 14, 2006. Dr. Goddard’s amended Employment Agreement is attached hereto as Exhibit 10.4.

ITEM 9.01. Financial Statements and Exhibits.


Exhibit No.		Description
10.1		Form of non-qualified option agreement for U.S.-based executive officers of OSI Pharmaceuticals, Inc.

10.2		Form of non-qualified option agreement for U.K.-based employees of OSI Pharmaceuticals, Inc.

10.3		Form of non-qualified option agreement for non-management directors of OSI Pharmaceuticals, Inc.

10.4		Employment Agreement between OSI Pharmaceuticals, Inc. and Colin Goddard, Ph.D, dated June 14, 2006, as amended on June 21, 2006.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date: June 22, 2006	OSI PHARMACEUTICALS, INC.
	By:	/s/ Barbara A. Wood
		Barbara A. Wood
		Vice President, General Counsel and Secretary

EXHIBIT INDEX


Exhibit No.		Description
10.1		Form of non-qualified option agreement for U.S.-based executive officers of OSI Pharmaceuticals, Inc.

10.2		Form of non-qualified option agreement for U.K.-based employees of OSI Pharmaceuticals, Inc.

10.3		Form of non-qualified option agreement for non-management directors of OSI Pharmaceuticals, Inc.

10.4		Employment Agreement between OSI Pharmaceuticals, Inc. and Colin Goddard, Ph.D, dated June 14, 2006, as amended on June 21, 2006.

EX-10.1 2 y22540exv10w1.htm EX-10.1: FORM OF NON-QUALIFIED OPTION AGREEMENT EX-10.1

Exhibit 10.1

OSI PHARMACEUTICALS, INC.

1999 INCENTIVE AND NON-QUALIFIED STOCK OPTION PLAN

STOCK OPTION AGREEMENT

THIS NON-QUALIFIED STOCK OPTION AGREEMENT is dated as of ___, 2006 by and between OSI PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and [Executive Officer] (the “Optionee”), an employee of the Company.

Pursuant to the OSI Pharmaceuticals, Inc. 1999 Incentive and Non-Qualified Stock Option Plan (the “Plan”), a copy of which has been provided to Optionee as of the date hereof, the Compensation Committee of the Board of Directors approved on June 13, 2006 (the “Grant Date”) the grant to the Optionee of a non-qualified stock option to purchase shares of the Company’s common stock, par value $.01 per share (the “Common Stock”). The option granted herein is (i) made pursuant to the OSI Pharmaceuticals, Inc. 1999 Incentive and Non-Qualified Stock Option Plan (the “Plan”), a copy of which has been provided to Optionee as of the date hereof and (ii) not intended to qualify as an “incentive stock option” as defined in Section 422 of the Internal Revenue Code of 1986, as amended.

W I T N E S S E T H:

1. Grant. On the Grant Date, the Company granted to the Optionee an option (the “Option”) to purchase on the terms and conditions set forth herein and in the Plan all or any part of an aggregate of ___shares of Common Stock (the “Option Shares”), at the purchase price of $ _____ per share (the “Option Price”).

2. Vesting. The Optionee shall have the cumulative right to exercise the Option over a period of four years, with one quarter (25%) of the Option Shares becoming exercisable on each of the next four anniversaries of the Grant Date, with any fractional number of Option Shares that would otherwise become exercisable as of any such anniversary rounded to a whole integer as determined in the discretion of the Committee.

3. Term. The Option shall terminate in all events at 5:00 p.m. (local New York, New York time) on June 12, 2013 (the “Termination Date”), unless sooner terminated as provided in Subparagraphs (a) or (b) below.

(a) Termination of Employment or Service. The Option shall terminate and shall no longer be exercisable ninety (90) days after the Optionee’s employment (or service as an officer or consultant) with the Company and any parent or subsidiary of the Company terminates, unless such termination of employment or service was caused by the Optionee’s death or Retirement (as defined in the Plan). The death or Retirement of the Optionee shall not affect the remaining term of the Option. Following a termination of employment or service (including due to death or Retirement), the Optionee (or the Optionee’s heirs or personal representatives if Optionee is deceased) may, during the remaining term of the Option, purchase any remaining

Option Shares which could have been purchased on the date Optionee’s employment or service was terminated, but may not purchase any Option Shares which would otherwise have first become purchasable following such termination of employment or service.

(b) Sale or Reorganization. As provided in Section 6(h) of the Plan, if the Company is merged or consolidated with another corporation, or if the property or stock of the Company is acquired by another corporation, or if there is a separation, reorganization or liquidation of the Company, the Board of Directors of the Company may, in its discretion, give Optionee a written notice that the Option will terminate thirty (30) days after the date of such written notice. In any such case, the Option will become immediately exercisable in full, notwithstanding Paragraph 2 above.

4. Method of Exercise and Payment.

(a) Method of Exercise. The Option shall be exercised through the Company’s broker-assisted stock option program (the “Broker Program”) in accordance with the terms and conditions of the Broker Program as may be in effect from time to time.

(b) Taxes. It shall be a condition to the performance of the Company’s obligation to issue or transfer Option Shares upon the exercise of the Option that the Optionee remit an amount sufficient to satisfy any federal, state and/or local tax withholding requirements arising in connection with the exercise of the Option or the issuance of Option Shares, other than stock transfer taxes, in each case in accordance with the terms and conditions of the Broker Program as may be in effect from time to time. If the Company for any reason does not require the Optionee to make a payment sufficient to satisfy such withholding requirements, any tax withholding payments made by the Company to any federal, state or local tax authority with respect to the exercise of the Option shall constitute a personal obligation of the Optionee to the Company, payable upon demand or, at the option of the Company, by deduction from future compensation payable to the Optionee.

(c) Partial Exercise. To the extent otherwise exercisable, the Option may be exercised in whole or in part, except that the Option may in no event be exercised with respect to fractional shares.

5. Transfers. Except as approved by the Committee, the Option is not transferable by the Optionee otherwise than by will or pursuant to the laws of descent and distribution in the event of the Optionee’s death, in which event the Option may be exercised by the heirs or legal representatives of the Optionee. The Option may be exercised during the lifetime of the Optionee only by the Optionee. Any attempt at assignment, transfer, pledge or disposition of the Option contrary to the provisions hereof or the levy of any execution, attachment or similar process upon the Option shall be null and void and without effect. Any exercise of the Option by a person other than the Optionee shall be accompanied by appropriate proofs of the right of such person to exercise the Option.

6. Adjustments on Changes in Common Stock. In the event that dividends payable in Common Stock during any fiscal year of the Company exceed in the aggregate five percent (5%)

of the Common Stock issued and outstanding at the beginning of the year, or in the event there is during any fiscal year of the Company one or more splits, subdivisions or combinations of shares of Common Stock resulting in an increase or decrease by more than five percent (5%) of the shares of Common Stock outstanding at the beginning of the year, the number of Option Shares deliverable upon the exercise thereafter of the Option shall be increased or decreased proportionately, as the case may be, without change in the aggregate purchase price payable upon exercise of the Option. Common Stock dividends, splits, subdivisions or combinations during any fiscal year which do not exceed in the aggregate five percent (5%) of the Common Stock issued and outstanding at the beginning of such year shall not result in any adjustment under the Option. All adjustments shall be made as of the day such action necessitating such adjustment becomes effective.

7. Legal Requirements.

(a) Listing Requirements. If at any time the Board of Directors shall determine, in its discretion, that the listing, registration, or qualification of any of the Option Shares upon any securities exchange or under any state or federal law, or the consent or approval of any governmental regulatory body, is necessary or desirable as a condition of, or in connection with, the granting of the Option or the issue, transfer or purchase of Option Shares hereunder, the Option may not be exercised in whole or in part unless such listing, registration, qualification, consent, or approval shall have been effected or obtained free of any conditions not acceptable to the Board of Directors.

(b) Securities Laws. The Company shall not be obligated to sell or issue any Option Shares in any manner in contravention of the Securities Act of 1933, as amended, or any state securities law. The Board of Directors or the Committee may, at any time, require, as a condition to the exercise of the Option, the representation or agreement of the Optionee to the effect that the Option Shares issuable upon exercise of the Option are acquired by the Optionee for investment purposes and not with a view to the resale or distribution thereof, and may require such other representations and documents as may be required to comply with applicable securities laws.

8. Administration. The Option has been granted pursuant to, and is subject to the terms and provisions of, the Plan. All terms used herein which are defined in the Plan and not otherwise defined herein shall have the same meanings as in the Plan. To the extent that the provisions hereof conflict with those of the Plan, the provisions of the Plan shall control. All decisions or interpretations made by the Committee (as designated under the Plan) regarding any issue or question arising under the Option or the Plan shall be final, binding and conclusive on the Company and the Optionee.

9. Rights as Stockholder. The Optionee shall have none of the rights of a stockholder with respect to the Option Shares unless and until such Option Shares shall be issued to the Optionee upon the exercise of the Option. Except as provided in Paragraph 6 above, no adjustments shall be made for dividends or other rights for which the record date is prior to the date the stock certificate is issued.

10. Continued Employment or Service. Nothing contained herein or in the Plan shall confer any right to continue in the employ or service of the Company or any parent or subsidiary of the Company or interfere in any way with the right of the Company or any parent or subsidiary of the Company to terminate the employment, services, responsibilities or duties of the Optionee at any time for any reason whatsoever.

11. Sale of Option Shares. Unless otherwise provided by the Committee, no Option Shares acquired upon exercise of the Option may be sold or otherwise disposed of by the Optionee within six months from the Grant Date.

12. Notices. Any notice to be given to the Company hereunder shall be delivered personally to the Secretary of the Company or mailed or delivered to the Company at its principal executive office, addressed to the attention of the Secretary, and any notice to be given to the Optionee hereunder shall be delivered personally or mailed or delivered to the Optionee at the address then appearing on the records of the Company. Such addresses may be changed at any time by notice from one party to the other. Notices given hereunder shall be in writing, and shall be deemed to have been duly given upon delivery thereof, if personally delivered, or three days after being deposited in the United States mail, registered or certified mail, properly addressed, with proper postage and fees prepaid, or one day after being deposited with a delivery service guaranteeing overnight delivery, properly addressed, with fees paid by the sender.

13. Governing Law. This Agreement will be interpreted and enforced under the laws of the State of New York, other than any conflicts or choice of law rule or principle that might otherwise refer construction or interpretation of this Agreement to the substantive law of another jurisdiction. The parties will submit any dispute or claim arising under this Agreement to the exclusive jurisdiction of the U.S. federal or New York state courts within the New York counties of New York, Nassau, or Suffolk, and the parties hereby submit to, and waive any objection to, personal jurisdiction and venue in such courts for such purpose.

14. Binding Effect. This agreement shall be binding upon and inure to the benefit of the parties hereto, including the successors and assigns of the Company and the heirs and personal representatives of the Optionee.

15. Counterparts. This Agreement may be executed simultaneously in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

IN WITNESS WHEREOF, the Company has granted this Option as of the day and year first above written.


		OSI PHARMACEUTICALS, INC.


		Name:		Michael G. Atieh
		Title:		Executive Vice President and
				Chief Financial Officer

		ACCEPTED BY (OPTIONEE):


		Name:


		Date

EX-10.2 3 y22540exv10w2.htm EX-10.2: FORM OF NON-QUALIFIED OPTION AGREEMENT EX-10.2

Exhibit 10.2

OSI PHARMACEUTICALS, INC.

1999 INCENTIVE AND NON-QUALIFIED
STOCK OPTION PLAN AGREEMENT

THIS NON-QUALIFIED STOCK OPTION (this “Option”) is dated as of June 21, 2006, by OSI PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), to [Employee] (the “Optionee”), an employee of Prosidion Limited (“the UK Subsidiary”). The Option is granted subject to a condition that any liability of the UK Subsidiary (as employer or former employer of the Optionee) to pay secondary national insurance contributions (“Secondary NIC”) in respect of the exercise, assignment or release of the Option shall be the liability of the Optionee and payable by the Optionee and that the Optionee shall be required to enter into an election in the form envisaged in Paragraph 313(1) of Schedule 1 to the Social Security Contributions and Benefits Act 1992 (“Election”) to that effect when required to do so by the UK Subsidiary provided that the Committee may in its discretion at any time or times release the Optionee from this liability or reduce his liability thereunder unless that Election has been entered into between the UK Subsidiary and the Optionee and that Election (or the legislation which provides for such an Election to be effective) does not allow for such an Election to be subsequently varied. For the avoidance of doubt the terms of the Election shall include a statement to the effect that the Optionee is liable to pay any Secondary NIC arising on the exercise of the Option even if he is no longer an employee of the UK Subsidiary and/or no longer resident in the United Kingdom at the date of exercise.

The Compensation Committee of the Board of Directors of the Company (the “Committee”) approved on (the “Grant Date”) the grant to the Optionee of a non-qualified stock option to purchase shares of the Company’s common stock, par value $.01 per share (the “Common Stock”), as hereinafter set forth. The option granted herein is (i) pursuant to the OSI Pharmaceuticals, Inc. 1999 Incentive and Non-Qualified Stock Option Plan (the “Plan”), a copy of which has been provided to Optionee as of the date hereof, and (ii) not intended to qualify as an “incentive stock option” as defined in Section 422 of the Internal Revenue Code of 1986, as amended.

W I T N E S S E T H:

1. Grant. On the Grant Date, the Company granted to the Optionee an option (the “Option”) to purchase on the terms and conditions set forth herein and in the Plan all or any part of an aggregate of shares of Common Stock (the “Option Shares”), at the purchase price of $ per share (the “Option Price”).

that would otherwise become exercisable as of any such anniversary rounded to a whole integer as determined in the discretion of the Committee.

a. Termination of Employment or Service. The Option shall terminate and shall no longer be exercisable ninety (90) days after the Optionee’s employment (or service as an officer or consultant) with the Company and any parent or subsidiary of the Company terminates, unless such termination of employment or service was caused by the Optionee’s death or Retirement (as defined in the Plan). The death or Retirement of the Optionee shall not affect the remaining term of the Option. Following a termination of employment or service (including due to death or Retirement), the Optionee (or the Optionee’s heirs or personal representatives if Optionee is deceased) may, during the remaining term of the Option, purchase any remaining Option Shares which could have been purchased on the date Optionee’s employment or service was terminated, but may not purchase any Option Shares which would otherwise have first become purchasable following such termination of employment or service.

b. Sale or Reorganization. As provided in Section 6(h) of the Plan, if the Company is merged or consolidated with another corporation, or if the property or stock of the Company is acquired by another corporation, or if there is a separation, reorganization or liquidation of the Company, the Board of Directors of the Company may, in its discretion, give Optionee a written notice that the Option will terminate thirty (30) days after the date of such written notice. In any such case, the Option will become immediately exercisable in full, notwithstanding Paragraph 2 above.

4. Method of Exercise and Payment.

a. Method of Exercise. Subject to Paragraph 4(c) below, the Option shall be exercised through the Company’s broker-assisted stock option program (the “Broker Program”), in accordance with the terms and conditions of the Broker Program as may be in effect from time to time.

b. Taxes. It shall be a condition to the performance of the Company’s obligation to issue or transfer Option Shares upon the exercise of the Option that the Optionee remit an amount on an indemnity basis sufficient to satisfy any federal, state and/or local tax withholding requirements (including any interest or penalties due in respect of such sums) arising in connection with the exercise of the Option or the issuance of Option Shares, other than stock transfer taxes, in each case in accordance with any terms and conditions of the Broker Program as may be in effect from time to time. If the Company for any reason does not require the Optionee to make a payment sufficient to satisfy such withholding requirements, any tax withholding payments (including any interest or penalties due in respect of such sums) made by the Company to any federal, state or local tax authority with respect to the exercise of the Option shall constitute a personal obligation of the Optionee to the Company, payable upon demand or, at the option of the Company, by deduction from future compensation payable to the Optionee.

-2-

c. National Insurance Contributions. No stock shall be allotted or transferred to the Optionee by the Company until the UK Subsidiary has received an amount in cash equal to the amount of the Secondary NIC for which the Optionee is liable under the terms of the Election (“the NIC Amount”). The Optionee shall by completing the Election grant to the UK Subsidiary (as employer or former employer of the Optionee) the irrevocable authority, as agent of the Optionee and on his behalf, to appoint an Independent Transfer Agent to act as agent of the Optionholder and on his behalf to sell or procure the sale of sufficient of the Stock acquired on the exercise, assignment or release of the Option and remit the net sale proceeds to the UK Subsidiary so that the net proceeds payable to the UK Subsidiary are so far as possible equal to but not less than the NIC Amount and the UK Subsidiary shall account to the Optionee for any balance. In this paragraph 4(c), “Independent Transfer Agent” means any person (other than the Company or any company affiliated with the Company or any individual affiliated with any such company) who is registered as a broker-dealer with the U.S. Securities and Exchange Commission and who is thereby able to sell and transfer shares in the Company on behalf of the Optionee.

d. Partial Exercise. To the extent otherwise exercisable, the Option may be exercised in whole or in part, except that the Option may in no event be exercised with respect to fractional shares.

5. Transfers. The Option is not transferable by the Optionee otherwise than by will or pursuant to the laws of descent and distribution in the event of the Optionee’s death, in which event the Option may be exercised by the heirs or legal representatives of the Optionee. The Option may be exercised during the lifetime of the Optionee only by the Optionee. Any attempt at assignment, transfer, pledge or disposition of the Option contrary to the provisions hereof or the levy of any execution, attachment or similar process upon the Option shall be null and void and without effect. Any exercise of the Option by a person other than the Optionee shall be accompanied by appropriate proofs of the right of such person to exercise the Option.

6. Adjustments on Changes in Common Stock. In the event that dividends payable in Common Stock during any fiscal year of the Company exceed in the aggregate five percent (5%) of the Common Stock issued and outstanding at the beginning of the year, or in the event there is during any fiscal year of the Company one or more splits, subdivisions or combinations of shares of Common Stock resulting in an increase or decrease by more than five percent (5%) of the shares of Common Stock outstanding at the beginning of the year, the number of Option Shares deliverable upon the exercise thereafter of the Option shall be increased or decreased proportionately, as the case may be, without change in the aggregate purchase price payable upon exercise of the Option. Common Stock dividends, splits, subdivisions or combinations during any fiscal year which do not exceed in the aggregate five percent (5%) of the Common Stock issued and outstanding at the beginning of such year shall not result in any adjustment under the Option. All adjustments shall be made as of the day such action necessitating such adjustment becomes effective.

7. Legal Requirements.

a. Listing Requirements. If at any time the Board of Directors of the Company shall determine, in its discretion, that the listing, registration, or qualification of any of the

-3-

Option Shares upon any securities exchange or under any state or federal law, or the consent or approval of any governmental regulatory body, is necessary or desirable as a condition of, or in connection with, the granting of the Option or the issue, transfer or purchase of Option Shares hereunder, the Option may not be exercised in whole or in part unless such listing, registration, qualification, consent, or approval shall have been effected or obtained free of any conditions not acceptable to the Board of Directors of the Company.

b. Securities Laws. The Company shall not be obligated to sell or issue any Option Shares in any manner in contravention of the Securities Act of 1933, as amended, or any state or foreign securities law. The Board of Directors of the Company or the Committee may, at any time, require, as a condition to the exercise of the Option, the representation or agreement of the Optionee to the effect that the Option Shares issuable upon exercise of the Option are acquired by the Optionee for investment purposes and not with a view to the resale or distribution thereof, and may require such other representations and documents as may be required to comply with applicable securities laws.

10. Continued Employment or Service. Nothing contained herein or in the Plan shall confer any right to continue in the employ or service of the UK Subsidiary, the Company or any parent or other subsidiary of the Company or interfere in any way with the right of the UK Subsidiary, the Company or any parent or other subsidiary of the Company to terminate the employment, services, responsibilities or duties of the Optionee at any time for any reason whatsoever.

-4-

shall be deemed to have been duly given upon delivery thereof, if personally delivered, or three days after being deposited in the United States mail, registered or certified mail, properly addressed, with proper postage and fees prepaid, or one day after being deposited with a delivery service guaranteeing overnight delivery, properly addressed, with fees paid by the sender.

13. Governing Law. This Option, the documents to be entered into pursuant thereto, and all matters arising from or connected with it are governed by and shall be construed in accordance with the laws of England and Wales.

14. Binding Effect. This Option shall be binding upon and inure to the benefit of the parties hereto, including the successors and assigns of the Company and the heirs and personal representatives of the Optionee.

15. Counterparts. This Option may be executed simultaneously in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

-5-

Exhibit 10.2

IN WITNESS WHEREOF, the Company has granted this Option as of the day and year first above written.


		OSI PHARMACEUTICALS, INC.




		Name:		Michael G. Atieh
		Title:		Executive Vice President and
				Chief Financial Officer

		ACCEPTED BY (OPTIONEE):


		Name:		[Employee]


		Date:

EX-10.3 4 y22540exv10w3.htm EX-10.3: FORM OF NON-QUALIFIED OPTION AGREEMENT EX-10.3

Exhibit 10.3

OSI PHARMACEUTICALS, INC.

1999 INCENTIVE AND NON-QUALIFIED STOCK OPTION PLAN

STOCK OPTION AGREEMENT

THIS NON-QUALIFIED STOCK OPTION AGREEMENT is dated as of ___, 2006 by and between OSI PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and [Director] (the “Optionee”), a director of the Company.

On April 19, 2006, the Compensation Committee of the Board of Directors of the Company (the “Committee”) approved changes to the compensation paid to the non-management directors, which included the automatic grant of a non-qualified stock option to purchase shares of the Company’s common stock, par value $.01 per share (the “Common Stock”) to each director upon the election or re-election of such director to the Board of Directors of the Company on June 14, 2006 (the “Grant Date”), as described herein. The option granted herein is (i) made pursuant to the OSI Pharmaceuticals, Inc. 1999 Incentive and Non-Qualified Stock Option Plan (the “Plan”), a copy of which has been provided to Optionee as of the date hereof and (ii) not intended to qualify as an “incentive stock option” as defined in Section 422 of the Internal Revenue Code of 1986, as amended.

W I T N E S S E T H:

(a) Termination of Employment or Service. The Option shall terminate and shall no longer be exercisable ninety (90) days after the Optionee’s service as a director of the Company terminates, unless such termination of service was caused by the Optionee’s death or Retirement (as defined in the Plan). The death or Retirement of the Optionee shall not affect the remaining term of the Option. Following a termination of service (including due to death or Retirement), the Optionee (or the Optionee’s heirs or personal representatives if Optionee is

deceased) may, during the remaining term of the Option, purchase any remaining Option Shares which could have been purchased on the date Optionee’s service was terminated, but may not purchase any Option Shares which would otherwise have first become purchasable following such termination of service.

4. Method of Exercise and Payment.

(c) Partial Exercise. To the extent otherwise exercisable, the Option may be exercised in whole or in part, except that the Option may in no event be exercised with respect to fractional shares.

7. Legal Requirements.

adjustments shall be made for dividends or other rights for which the record date is prior to the date the stock certificate is issued.

10. Sale of Option Shares. Unless otherwise provided by the Committee, no Option Shares acquired upon exercise of the Option may be sold or otherwise disposed of by the Optionee within six months from the Grant Date.

11. Notices. Any notice to be given to the Company hereunder shall be delivered personally to the Secretary of the Company or mailed or delivered to the Company at its principal executive office, addressed to the attention of the Secretary, and any notice to be given to the Optionee hereunder shall be delivered personally or mailed or delivered to the Optionee at the address then appearing on the records of the Company. Such addresses may be changed at any time by notice from one party to the other. Notices given hereunder shall be in writing, and shall be deemed to have been duly given upon delivery thereof, if personally delivered, or three days after being deposited in the United States mail, registered or certified mail, properly addressed, with proper postage and fees prepaid, or one day after being deposited with a delivery service guaranteeing overnight delivery, properly addressed, with fees paid by the sender.

12. Governing Law. This Agreement will be interpreted and enforced under the laws of the State of New York, other than any conflicts or choice of law rule or principle that might otherwise refer construction or interpretation of this Agreement to the substantive law of another jurisdiction. The parties will submit any dispute or claim arising under this Agreement to the exclusive jurisdiction of the U.S. federal or New York state courts within the New York counties of New York, Nassau, or Suffolk, and the parties hereby submit to, and waive any objection to, personal jurisdiction and venue in such courts for such purpose.

13. Binding Effect. This agreement shall be binding upon and inure to the benefit of the parties hereto, including the successors and assigns of the Company and the heirs and personal representatives of the Optionee.

14. Counterparts. This Agreement may be executed simultaneously in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

IN WITNESS WHEREOF, the Company has granted this Option as of the day and year first above written.


		OSI PHARMACEUTICALS, INC.


		Name:		Michael G. Atieh
		Title:		Executive Vice President and
				Chief Financial Officer

		ACCEPTED BY (OPTIONEE):


		Name:


		Date

EX-10.4 5 y22540exv10w4.htm EX-10.4: EMPLOYMENT AGREEMENT EX-10.4

Exhibit 10.4

EXECUTION COPY



		June 14, 2006

		Amended June 21, 2006

Colin Goddard, Ph.D.
c/o OSI Pharmaceuticals, Inc.
41 Pinelawn Road
Melville, New York 11747

Re: Employment Agreement

Dear Colin:

This letter is to confirm our understanding with respect to (i) your continuing employment by OSI Pharmaceuticals, Inc. (“OSI” and, together with Company Affiliates (as defined below), the “Company”), (ii) your agreement not to solicit employees or customers of the Company or any Company Affiliate, (iii) your agreement to protect and preserve information and property which is confidential and proprietary to the Company, and (iv) your agreement with respect to the ownership of inventions, ideas, copyrights and patents which may be used in the business of the Company (the terms and conditions agreed to in this letter are hereinafter referred to as the “Agreement”). As used herein, any presently existing parent, subsidiary or affiliate of OSI is referred to as a “Company Affiliate.” In consideration of the mutual promises and covenants contained in this Agreement, and for other good and valuable consideration, the receipt and sufficiency of which are hereby mutually acknowledged, we have agreed as follows:

1. Employment.

(a) Subject to the terms and conditions of this Agreement, the Company will employ you, and you will be employed by the Company and/or any Company Affiliate designated by the Company, as the Chief Executive Officer (the “CEO”) of the Company, reporting solely to the Company’s Board of Directors (the “Board”). You will have the responsibilities, duties and authority customarily performed, undertaken and exercised by a person in a similar executive capacity. The principal location at which you will perform such services will be the Company’s headquarters presently located at 41 Pinelawn Road, Melville, New York, although you will be available to perform services at any other Company facility and to travel as the needs of business may require.

(b) Devotion to Duties. While you are employed hereunder, you will, to the best of your ability, perform faithfully and diligently all duties assigned to you pursuant to this Agreement and will devote your necessary business time and energies to the business and affairs

of the Company. While you are employed hereunder, you will not undertake any other employment from any person or entity without the prior written consent of the Company. Notwithstanding the foregoing, nothing contained herein shall limit your ability to manage your own personal investments on your own personal time or from serving on no more than two outside boards of directors or advisory boards of a public company, so long as such activities do not (i) involve a business or organization which competes with the Company or any Company Affiliate (except, in the case of personal investments, you may own up to 1% of the outstanding capital stock of a corporation if, at the time of your acquisition such stock is listed on a national securities exchange, is reported on NASDAQ, or is regularly traded in the over-the-counter market by a member of a national securities exchange), (ii) interfere or conflict with the performance of your duties as an employee of the Company or any Company Affiliate of the Company, or (iii) otherwise result in a breach of any of the provisions of this Agreement.

2. Term. Except for earlier termination as provided for in Section 4 hereof, your employment under this Agreement (the “Employment Term”) shall be for an initial term commencing on the date hereof (the “Effective Date”) and ending on the third anniversary of the Effective Date (the “Initial Term”). Unless written notice is given of an intent not to extend the Initial Term or any extension thereof by you or the Company at least 90 days prior to an anniversary of the Effective Date, the Employment Term shall be deemed, as of such 90^th day, to have been extended for an additional 12-month period unless otherwise terminated as provided for in Section 4 hereof. In the event the Company elects not to renew the Employment Term, you shall be entitled to the payments and benefits set forth in Section 6(c).

3. Compensation.

(a) Base Salary. While you are employed hereunder, the Company will pay you a base salary at the annual rate of $600,000 (the “Base Salary”). Your Base Salary will be reviewed on an annual basis each December (or such other time as determined by the Compensation Committee of the Board), commencing with December, 2006, and may be increased (but not decreased) as a result of any such review. The Base Salary will be payable in equal installments in accordance with the Company’s payroll practices as in effect from time to time. The Company will deduct from each such installment all amounts required to be deducted or withheld under applicable law or under any employee benefit plan in which you participate.

(b) Bonus. In addition to the Base Salary, for each fiscal year of the Company ending during the Employment Term, beginning with the 2006 fiscal year, you will be eligible to receive a target bonus of 100% of the Base Salary, determined and payable in accordance with the Company’s practices applicable to bonuses paid to its executives and payable on such date as the Company pays bonuses to its executives generally but no later than February 28^th of the year following the year for which such bonus is paid. The Company’s bonus system is a discretionary annual performance-based incentive bonus system, approved by the Company’s Board, and is based upon a combination of personal and corporate performance contributing to your maximum target. Bonuses are determined in December of each year.

(c) Equity Compensation. On each date that annual stock options or other equity compensation, including restricted stock, restricted stock units or deferred stock units, are granted by the Company to its executive management group, so long as you then remain in the

employ of the Company, the Company will grant you stock options or other equity compensation (an “Annual Equity Grant”) in respect of a number of shares of Common Stock to be determined by the Compensation Committee of the Board based upon your grade level, which during the Employment Term shall be the highest of any of the annual equity grants to executive officers of the Company. The terms and conditions of each Annual Equity Grant will be as set forth in the OSI Pharmaceuticals, Inc. Amended and Restated Stock Incentive Plan and accompanying agreement or agreements evidencing the grant or other applicable plans or agreements then in effect with regard to such Annual Equity Grant. Notwithstanding the foregoing, each Annual Equity Grant (as well as stock options and other equity compensation granted prior to the date of this Agreement) shall vest and be fully exercisable upon a Change in Control (as defined in Section 7) or upon a termination of your employment by the Company “without cause” (as defined in Section 4(c)) or by you for “good reason” (as defined in Section 4(d)).

(d) Vacation. You will be entitled to 25 paid vacation days in each calendar year, including 2006, and paid holidays plus personal days in accordance with the Company’s policies for its senior executives as in effect from time to time.

(e) Fringe Benefits. In addition to the equity compensation provided for herein, you will be entitled to participate in employee benefit plans which the Company provides or may establish for the benefit of its senior executives generally (for example, term life, disability, medical, dental and other insurance, retirement, pension, profit-sharing and similar plans) (collectively, the “Fringe Benefits”). Your eligibility to participate in the Fringe Benefits and receive benefits thereunder will be subject to the plan documents governing such Fringe Benefits. Without limiting the foregoing, during the Employment Term you will be provided with individual long term disability coverage (which the Company may provide directly or through insurance) providing benefits equal to at least 65% of your Base Salary if you experience a Permanent Disability (as defined in Section 4(b)). The Company will structure all applicable premium payments so that any disability payments made to you in the event of a Permanent Disability will not be considered taxable income to you. Except as expressly provided in this Agreement, the Company shall not be required to establish or maintain any Fringe Benefits.

(f) Company Car. The Company will provide you with an approved company car and will reimburse you for related expenses in accordance with the Company’s policy for its senior executives as in effect from time to time.

(g) Reimbursement of Expenses. Upon presentation of documentation of such expenses reasonably satisfactory to the Company, the Company will reimburse you for all ordinary and reasonable out-of-pocket business expenses that are reasonably incurred by you in furtherance of the Company’s business in accordance with the Company’s policies with respect thereto as in effect from time to time.

4. Termination. The Employment Term shall end upon the earliest of the following to occur:

(a) Your death.

(b) Upon written notice to you of termination as a result of your Permanent Disability. “Permanent Disability” means you are, by reason of any medically determinable

physical or mental impairment which can be expected to result in death or can be expected to last for a continuous period of not less than 12 months, unable to perform substantially all of your duties under this Agreement. Determinations of the foregoing shall be made by a qualified physician with no history of prior dealings with you or the Company, as reasonably agreed upon by you (or, if you are unable to make such selection, by an adult member of your immediate family) and the Company. Such physician’s written determination of your Permanent Disability shall, upon delivery to the Company, be final and conclusive for purposes of this Agreement.

(c) Your termination by the Company for “cause” as evidenced by, and effective upon, delivery by the Company to you of a Notice of Termination (as defined in Section 5 below). “Cause” shall mean, for purposes of this Agreement, (i) an act of fraud or embezzlement against the Company or an unauthorized disclosure of Confidential Information (as defined in Section 9(a)(iv) hereof) of the Company, in each case which is willful and results in material damage to the Company, (ii) any criminal violation of the Securities Act of 1933 or the Securities Exchange Act of 1934, (iii) your conviction (or a plea of nolo contendere) of any felony, (iv) your gross neglect of your duties or your willful and continuing refusal to perform your duties, provided you have been given written notice of such neglect or refusal and within 30 days have failed to cure such neglect and refusal, or (v) your material willful misconduct with respect to the business or affairs of the Company.

(d) Your termination of your employment for “good reason” by delivering to the Company a Notice of Termination (as defined in Section 5 below) not less than 30 days prior to the effective date of such termination. For purposes of this Agreement, “good reason” shall mean the occurrence of any of the events hereinafter set forth which are not cured by the Company (to the extent cure is possible) within 30 days after the Company has received written notice from you specifying the particular events or conditions which constitute “good reason”:

(i) a material reduction in your duties, title, responsibilities, authority, status, or reporting responsibilities (including as specifically provided herein) unless you have previously consented to such reduction (which consent may be given or withheld in your sole discretion);

(ii) your failure to be reelected to the Board and, as a result thereof, your service on the Board ceases;

(iii) a reduction in your Base Salary or the target rate of your bonus;

(iv) a material failure to pay or provide Fringe Benefits or other benefits described in this Agreement or any other material breach of this Agreement by the Company;

(v) the Company’s requiring you to be based more than 50 miles from the Company’s current headquarters in Melville, New York or to any location for which the average commute from your residence exceeds one hour; or

(vi) a Change in Control (as defined in Section 7).

(e) Termination of your employment by the Company “without cause” by delivery by the Company to you of a Notice of Termination (as defined in Section 5 below) not less than 30 days prior to the effective date of such termination. Your termination by the Company shall be considered to be “without cause” if you are terminated or dismissed by the Company for reasons other than death, Permanent Disability or for “cause”.

(f) Your termination of your employment “without good reason” by delivery by you to the Company of a Notice of Termination (as defined in Section 5 below). Your termination of your employment shall be considered to be “without good reason” unless you resign for “good reason” (as defined in Section 4(d)).

5. Notice of Termination. Any termination by the Company or by you shall be communicated by a written “Notice of Termination” to the other party hereto. A “Notice of Termination” shall mean a notice which indicates a termination date and the specific termination provision in this Agreement relied upon and which sets forth in reasonable detail the facts and circumstances claimed to provide a basis for termination under the provision so indicated.

6. Payments Upon Termination.

(a) Upon termination of your employment for any reason you will become entitled to (i) any accrued and unpaid Base Salary up to the date of termination, (ii) any accrued and unpaid vacation pay up to the date of termination, and (iii) an amount equal to the bonus that you would have been entitled to receive for the fiscal year in which your termination occurs had you continued to be employed until the end of such fiscal year, multiplied by a fraction (A) the numerator of which is the number of days in such fiscal year through the termination date and (B) the denominator or which is 365 ((i), (ii) and (iii) being collectively referred to as the “Accrued Compensation”).

(b) Upon termination of your employment due to death or Permanent Disability you (or your estate, as the case may be) will be entitled to receive your Accrued Compensation.

(c) Upon a termination of your employment by the Company “without cause” or by you “for good reason”, or following the expiration of the Employment Term if the Company elects not to renew the Employment Term, in addition to Accrued Compensation, subject to Section 6(e) below you will become entitled to (i) your Base Salary at the rate in effect as of the time of termination of your employment for 36 months following the date of termination, and (ii) continued coverage for 36 months following termination under any health, dental and disability program in which you were participating as of the time of termination of your employment, at levels comparable to those in effect as of the time of such termination.

(d) You shall not be required to mitigate the amount of any payment provided for under this Section 6 by seeking other employment or otherwise and no payment shall be offset or reduced by the amount of any compensation or benefits provided to you in any subsequent employment. The Company’s obligation to make the payments provided for in this Section 6 and

otherwise perform its obligations hereunder shall not be affected by any circumstances, including, without limitation, set-off, counterclaim, recoupment, defense or other claim, right or action which the Company may have against you or others.

(e) Any payments under Section 6(b) or (c) to which you may become entitled will not commence until the first day of the seventh month following the date your employment with the Company is terminated, and shall continue on the first day of each month thereafter (as applicable), so as to avoid any adverse tax consequences with respect to Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”), or any successor statute, regulation and guidance thereto. With respect to the continued monthly payments that may become due to you under Section 6(c)(i) and (iii), on the first day of the seventh month following the termination of your employment, you shall receive an amount equal to seven monthly payments otherwise due to you under the terms of Section 6(c)(i) and (iii), and thereafter, you shall receive a pro-rata monthly payment on the first day of each month until all payments due under the terms of Section 6(c)(i) and (iii) have been fully paid.

7. Change in Control. For purposes of this Agreement, a “Change in Control” shall occur on the date that:

(a) any one person, entity or group acquires ownership of capital stock of the Company that, together with the capital stock of the Company already held by such person, entity or group, constitutes more than 50% of the total fair market value or total voting power of the capital stock of the Company; provided, however, if any one person, entity or group is considered to own more than 50% of the total fair market value or total voting power of the capital stock of the Company, the acquisition of additional capital stock by the same person, entity or group shall not be deemed to be a Change in Control;

(b) any one person, entity or group acquires (or has acquired during the 12-month period ending on the date of the most recent acquisition by such person, entity or group) ownership of capital stock of the Company possessing 35% or more of the total voting power of the capital stock of Company;

(c) a majority of members of the Board is replaced during any 12-month period by directors whose appointment or election is not endorsed by the nominating committee of the Board prior to the date of the appointment or election; or

(d) any one person, entity or group acquires (or has acquired during the 12-month period ending on the date of the most recent acquisition by such person, entity or group) assets from the Company that have a total gross fair market value at least equal to 40% of the total gross fair market value of all of the assets of the Company immediately prior to such acquisition or acquisitions; provided, however, a transfer of assets by the Company shall not deemed to be a Change in Control if the assets are transferred to (i) a shareholder of the Company (immediately before the asset transfer) in exchange for or with respect to its capital stock in the Company, (ii) an entity, 50% or more of the total value or voting power of which is owned, directly or indirectly, by the Company, (iii) a person, entity or group that owns, directly or indirectly, 50% or more of the total value or voting power of all the outstanding capital stock of the Company, or

(iv) an entity, at least 50% of the total value or voting power of which is owned, directly or indirectly, by a person, entity or group described in subparagraph (iii) above. In all respects, the definition of “Change in Control” shall be interpreted to comply with Code Section 409A, and the provisions of Treasury Notice 2005-1, and any successor statute, regulation and guidance thereto.

8. Excise Tax. If it is determined that the amounts payable to you under this Agreement, when considered together with any amounts payable to you in connection with a Change in Control, cause such payments to be treated as excess parachute payments within the meaning of Section 280G of the Code, then the Company will make an additional “gross up” payment to you in order to pay for any additional tax imposed on you pursuant to Section 4999 of the Code.

9. Prohibited Activities.

(a) Certain Acknowledgements and Agreements.

(i) We have discussed, and you recognize and acknowledge the competitive and proprietary aspects of the business of the Company.

(ii) You acknowledge that your employment by the Company creates a relationship of confidence and trust between the Company and you with respect to certain information relating to the business and affairs of the Company or applicable to the business of any client, customer, consultant, partner, external collaborator or service provider of the Company, which may be made known to you by the Company or by any client, customer, consultant, partner, external collaborator or service provider of the Company, or learned by you during the period of your affiliation with the Company.

(iii) You further acknowledge that, while you are employed hereunder, the Company will furnish, disclose or make available to you Confidential Information (as defined in Section 9 (a) (iv) below) related to the business of the Company (whether or not the information has commercial value to the Company’s business). You also acknowledge that such Confidential Information has been developed and will be developed by the Company through the expenditure by the Company of substantial time, effort and money and that all such Confidential Information could be used by you to compete with the Company. You also acknowledge that if you become employed or affiliated with any competitor of the Company, it is possible that you would disclose Confidential Information to such competitor and would use Confidential Information, knowingly or unknowingly, on behalf of such competitor.

(iv) For purposes of this Agreement, “Confidential Information” means confidential and proprietary information of the Company, whether in written, oral, electronic or other form, including, without limitation, systems, processes, formulae, data, functional specifications, computer software, programs and displays, know-how, improvements, discoveries, inventions, developments, designs, techniques, marketing plans, strategies, forecasts, new and proposed products and technologies, unpublished financial statements and

financial information, business plans, budgets, projections, licenses, prices, costs, training methods and materials, sales prospects, and customer, supplier, manufacturer, collaborator, partner, and client lists and any and all intellectual properties, including any scientific, technical or trade secrets of the Company or of any third party provided to you or the Company under a condition of confidentiality, provided that Confidential Information will not include information that is in the public domain other than through any fault or act by you or is lawfully and in good faith made available to you by a third party under no obligation of confidentiality with respect thereto.

(b) Covenants. While you are employed hereunder and for a period of six months following the termination of your employment hereunder for any reason or for no reason, you will not, without the prior written consent of the Company:

(i) Engage, directly or indirectly, for your benefit or the benefit of others, in any activity or employment in the performance of which any Confidential Information obtained during the course of your employment would, by necessity, need to be disclosed by you in order to engage in any such activity or employment. This covenant shall not be construed to limit in any way your obligation not to use or disclose Confidential Information as set forth in Section 9 below.

(ii) Either individually or on behalf of or through any third party, directly or indirectly, solicit, divert or appropriate or attempt to solicit, divert or appropriate, any customers of the Company or any prospective customers with respect to which the Company has developed or made a sales presentation (or similar offering of services) for the purpose of directly competing with the Company with respect to the Company’s “principal marketed products” (i.e., those products which are in the first or second detail position) or its development candidates which have material financial significance to the Company and which are in Phase III programs; or

(iii) Either individually or on behalf of or through any third party, directly or indirectly, (A) solicit, entice or persuade or attempt to solicit, entice or persuade any employees of or consultants to the Company to leave the service of the Company for any reason, or (B) employ, cause to be employed, or solicit the employment of, any employees of or consultants to the Company while any such person is providing services to the Company or within six months after any such person has ceased providing services to the Company; or

(iv) Either individually or on behalf of or through any third party, directly or indirectly, interfere with, or attempt to interfere with, the relations between the Company and any manufacturer or supplier to or customer of the Company.

(c) Reasonableness of Restrictions. You understand that the provisions set forth in Section 9(b) are not meant to prevent you from earning a living or fostering your career. They are intended, however, to prevent competitors of the Company from gaining an unfair advantage from your knowledge of Confidential Information. You understand that, by making any other employer aware of the provisions set forth in this Section 9, that employer can take such action as to avoid your breach of this Section 9.

(d) Survival of Acknowledgements and Agreements. Your acknowledgements and agreements set forth in this Section 9 will survive the termination of this Agreement and the termination of your employment hereunder for any reason or for no reason.

10. Protected Information. All Confidential Information shall be the sole property of the Company and its assigns. You hereby assign to the Company any right you may have or acquire in such Confidential Information. You will at all times, both during the period while you are employed hereunder and after the termination of this Agreement and the termination of your employment hereunder for any reason or for no reason, maintain in confidence and will not, without the prior written consent of the Company, use, except as required in the course of performance of your duties for the Company or by court order, disclose or give to others any Confidential Information. In the event you are questioned by anyone not employed by the Company or by an employee of or a consultant to the Company not authorized to receive Confidential Information, in regard to any Confidential Information, or concerning any fact or circumstance relating thereto, you will promptly notify the Company. Upon the termination of your employment hereunder for any reason or for no reason, or if the Company otherwise requests, you will return to the Company all tangible Confidential Information and copies thereof (regardless how such Confidential Information or copies are maintained). The terms of this Section 10 are in addition to, and not in lieu of, any statutory or other contractual or legal obligation that you may have relating to the protection of the Company’s Confidential Information. The terms of this Section 10 will survive indefinitely any termination of this Agreement and/or any termination of your employment hereunder for any reason or for no reason.

11. Ownership of Ideas, Copyrights and Patents.

(a) Property of the Company. All ideas, discoveries, creations, manuscripts and properties, innovations, improvements, know-how, inventions, designs, developments, apparatus, techniques, methods, biological processes, cell lines, laboratory notebooks and formulae (collectively, the “Inventions”) which may be used in the current or planned business of the Company or which in any way relates to such business, whether patentable, copyrightable or not, which you may conceive, reduce to practice or develop while you are employed hereunder, alone or in conjunction with another or others, whether during or out of regular business hours, whether or not on the Company’s premises or with the use of its equipment, and whether at the request or upon the suggestion of the Company or otherwise, will be the sole and exclusive property of the Company, and that you will not publish any of the Inventions without the prior written consent of the Company. Without limiting the foregoing, you also acknowledge that all original works of authorship which are made by you (solely or jointly with others) within the scope of your employment or which relate to the business of the Company and which are protectable by copyright are “works made for hire” pursuant to the United States Copyright Act

(17 U.S.C. Section 101). You will promptly disclose to the Company all of the foregoing and you hereby assign to the Company all of your right, title and interest in and to all of the foregoing. You further represent that, to the best of your knowledge and belief, none of the Inventions will violate or infringe upon any right, patent, copyright, trademark or right of privacy, or constitute libel or slander against or violate any other rights of any person, firm or corporation, and that you will use your best efforts to prevent any such violation.

(b) Cooperation. At any time during your employment hereunder or after the termination of your employment hereunder for any reason or for no reason, you will cooperate reasonably with the Company and its attorneys and agents in the preparation and filing of all papers and other documents as may be required to perfect the Company’s rights in and to any of such Inventions, including, without limitation, joining in any proceeding to obtain letters patent, copyrights, trademarks or other legal rights with respect to any such Inventions in the United States and in any and all other countries, provided that the Company will bear the expense of such proceedings and will compensate you at a reasonable agreed upon daily rate for your time, and that any patent or other legal right so issued to you personally will be assigned by you to the Company without charge by you.

(c) Licensing and Use of Inventions. With respect to any Inventions, and work of any similar nature (from any source), whenever created, which you have not prepared or originated in the performance of your employment, but which you provide to the Company or incorporate in any Company product or system, you hereby grant to the Company a royalty-free, fully paid-up, non-exclusive, perpetual and irrevocable license throughout the world to use, modify, create derivative works from, disclose, publish, translate, reproduce, deliver, perform, dispose of, and to authorize others so to do, all such Inventions. You will not include in any Inventions you deliver to the Company or use on its behalf, without the prior written approval of the Company, any material which is or will be patented, copyrighted or trademarked by you or others unless you provide the Company with the written permission of the holder of any patent, copyright or trademark owner for the Company to use such material in a manner consistent with then-current Company policy.

12. Records. Upon termination of your employment hereunder for any reason or for no reason and at any other time requested by the Company, you will deliver to the Company any property of the Company which may be in your possession, including products, materials, memoranda, notes, records, reports, or other documents or photocopies of the same.

13. Representations. You hereby represent and warrant to the Company that you understand this Agreement, that you enter into this Agreement voluntarily and that your employment under this Agreement will not conflict with any legal duty owed by you to any other party, or with any agreement to which you are a party or by which you are bound, including, without limitation, any non-competition or non-solicitation provision contained in any such agreement.

14. General.

(a) Notices. All notices, requests, consents and other communications hereunder which are required to be provided, or which the sender elects to provide, in writing, will

be addressed to the receiving party’s address set forth above or to such other address as a party may designate by notice hereunder, and will be either (i) delivered by hand, (ii) sent by overnight courier, or (iii) sent by registered or certified mail, return receipt requested, postage prepaid. All notices, requests, consents and other communications hereunder will be deemed to have been given either (i) if by hand, at the time of the delivery thereof to the receiving party at the address of such party set forth above, (ii) if sent by overnight courier, on the next business day following the day such notice is delivered to the courier service, or (iii) if sent by registered or certified mail, on the fifth business day following the day such mailing is made.

(b) Entire Agreement. This Agreement, and the other agreements specifically referred to herein, embodies the entire agreement and understanding between the parties hereto with respect to the subject matter hereof and supersedes all prior oral or written agreements and understandings relating to the subject matter hereof, including your existing Employment Agreement dated as of April 30, 1998. No statement, representation, warranty, covenant or agreement of any kind not expressly set forth in this Agreement will affect, or be used to interpret, change or restrict, the express terms and provisions of this Agreement.

(c) Modifications and Amendments. The terms and provisions of this Agreement may be modified or amended only by written agreement executed by the parties hereto. Notwithstanding the foregoing, the Company and you agree to jointly execute an amendment to modify this Agreement to the extent necessary to comply with the requirements of Code Section 409A, or any successor statute, regulation and guidance thereto; provided that no such amendment shall increase the total financial obligation of the Company under this Agreement.

(d) Waivers and Consents. The terms and provisions of this Agreement may be waived, or consent for the departure therefrom granted, only by written document executed by the party entitled to the benefits of such terms or provisions. No such waiver or consent will be deemed to be or will constitute a waiver or consent with respect to any other terms or provisions of this Agreement, whether or not similar. Each such waiver or consent will be effective only in the specific instance and for the purpose for which it was given, and will not constitute a continuing waiver or consent.

(e) Assignment. The Company may assign its rights and obligations hereunder to any person or entity that succeeds to all or substantially all of the Company’s business or that aspect of the Company’s business in which you are principally involved or to any Company Affiliate; provided, that the Company shall remain responsible for any payments and obligations to you to the extent any assignee fails to fulfill such payments and obligations. You may not assign your rights and obligations under this Agreement without the prior written consent of the Company and any such attempted assignment by you without the prior written consent of the Company will be void.

(f) Benefit. All statements, representations, warranties, covenants and agreements in this Agreement will be binding on the parties hereto and will inure to the benefit of the respective successors and permitted assigns of each party hereto. Nothing in this Agreement will be construed to create any rights or obligations except between the Company and you, except for your obligations to the Company as set forth herein, and no person or entity (except for a

Company Affiliate as set forth herein) will be regarded as a third-party beneficiary of this Agreement.

(g) Governing Law. This Agreement and the rights and obligations of the parties hereunder will be construed in accordance with and governed by the laws of the State of New York, without giving effect to the conflict of law principles thereof.

(h) Jurisdiction, Venue and Service of Process. Any legal action or proceeding with respect to this Agreement that is not subject to arbitration pursuant to Section 15 (i) below will be brought in the courts of Suffolk County, New York. By execution and delivery of this Agreement, each of the parties hereto accepts for itself and in respect of its property, generally and unconditionally, the exclusive jurisdiction of the aforesaid courts.

(i) Arbitration. Any controversy, dispute or claim arising out of or in connection with this Agreement, other than a controversy, dispute or claim arising under Section 9, 10 or 11 hereof, will be settled by final and binding arbitration to be conducted in New York, New York pursuant to the national rules for the resolution of employment disputes of the American Arbitration Association then in effect. The decision or award in any such arbitration will be final and binding upon the parties and judgment upon such decision or award may be entered in any court of competent jurisdiction or application may be made to any such court for judicial acceptance of such decision or award and an order of enforcement. In the event that any procedural matter is not covered by the aforesaid rules, the procedural law of New York will govern. Any disagreement as to whether a particular dispute is arbitrable under this Agreement shall itself be subject to arbitration in accordance with the procedures set forth herein. The fees of the arbitrators shall be paid by the Company.

(j) WAIVER OF JURY TRIAL. ANY ACTION, DEMAND, CLAIM OR COUNTERCLAIM ARISING UNDER OR RELATING TO THIS AGREEMENT THAT IS NOT SUBJECT TO ARBITRATION PURSUANT TO SECTION 15(i) ABOVE WILL BE RESOLVED BY A JUDGE ALONE AND EACH OF YOU AND THE COMPANY WAIVE ANY RIGHT TO A JURY TRIAL THEREOF.

(k) Severability. The parties intend this Agreement to be enforced as written. However, (i) if any portion or provision of this Agreement is to any extent declared illegal or unenforceable by a duly authorized court having jurisdiction, then the remainder of this Agreement, or the application of such portion or provision in circumstances other than those as to which it is so declared illegal or unenforceable, will not be affected thereby, and each portion and provision of this Agreement will be valid and enforceable to the fullest extent permitted by law and (ii) if any provision, or part thereof, is held to be unenforceable because of the duration of such provision, the geographic area covered thereby, or other aspect or scope of such provision, the court making such determination will have the power to reduce the duration, geographic area of such provision, or other aspect or scope of such provision, and/or to delete specific words and phrases (“blue-penciling”), and in its reduced or blue-penciled form, such provision will then be enforceable and will be enforced.

(l) Injunctive Relief. You hereby expressly acknowledge that any breach or threatened breach of any of the terms and/or conditions set forth in Section 9, 10 or 11 of this

Agreement will result in substantial, continuing and irreparable injury to the Company. Therefore, in addition to any other remedy that may be available to the Company, the Company will be entitled to seek injunctive or other equitable relief by a court of appropriate jurisdiction in the event of any breach or threatened breach of the terms of Section 9, 10 or 11 of this Agreement. The period during which the covenants contained in Section 9 will apply will be extended by any periods during which you are found by a court to have been in violation of such covenants.

(m) No Waiver of Rights, Powers and Remedies. No failure or delay by a party hereto in exercising any right, power or remedy under this Agreement, and no course of dealing between the parties hereto, will operate as a waiver of any such right, power or remedy of the party. No single or partial exercise of any right, power or remedy under this Agreement by a party hereto, nor any abandonment or discontinuance of steps to enforce any such right, power or remedy, will preclude such party from any other or further exercise thereof or the exercise of any other right, power or remedy hereunder. The election of any remedy by a party hereto will not constitute a waiver of the right of such party to pursue other available remedies. No notice to or demand on a party not expressly required under this Agreement will entitle the party receiving such notice or demand to any other or further notice or demand in similar or other circumstances or constitute a waiver of the rights of the party giving such notice or demand to any other or further action in any circumstances without such notice or demand.

(n) Counterparts. This Agreement may be executed in two or more counterparts, and by different parties hereto on separate counterparts, each of which will be deemed an original, but all of which together will constitute one and the same instrument.

(o) Opportunity to Review. You hereby acknowledge that you have had adequate opportunity to review these terms and conditions and to reflect upon and consider the terms and conditions of this Agreement, and that you have had the opportunity to consult with counsel of your own choosing regarding such terms. You further acknowledge that you fully understand the terms of this Agreement and have voluntarily executed this Agreement.

(p) Survival of the Company’s Obligations. Notwithstanding the termination of this agreement pursuant to Section 4, the Company’s obligation to make payments and provide benefits to you as set forth in Section 6 will remain in effect.

(q) Expenses. The Company shall bear its own fees and expenses incurred in connection with the preparation, negotiation, execution and delivery of this Agreement and shall pay or reimburse you for your fees and expenses (including, legal fees and expenses) incurred in connection with the same.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

If the foregoing accurately sets forth our agreement, please so indicate by signing and returning to us the enclosed copy of this Agreement.


		Very truly yours,

		OSI Pharmaceuticals, Inc.

		By: Name:		/s/ Robert Ingram Robert A. Ingram
		Title:		Chairman, duly authorized


Accepted and Approved:

/s/ Colin Goddard		6/21/2006
Colin Goddard, Ph.D.		Date

-----END PRIVACY-ENHANCED MESSAGE-----

Table of Contents

Table of Contents

Table of Contents

Table of Contents